NEW YORK, April 19 (GenomeWeb News) - Icoria said today that it will use its metabolomics and gene-expression technology to characterize ADMET Technologies' human adult hepatocytes for predictive toxicology screening.
Under the agreement, ADMET will provide Icoria with liver cells from patients with a diversity of medical conditions. Icoria will then use its metabolomics, gene expression, and pathway analysis technologies to develop biological profiles and correlate these with differing sensitivities to various classes of hepatotoxic drugs, the companies said.
Icoria will retain the rights to commercial development of any novel diagnostic biomarkers discovered during the research. Further financial details were not disclosed.
In March, Icoria announced it was selling its agricultural genomics assets to Monsanto, and would reposition itself to focus on biomarker discovery for diabetes, obesity, and liver injury using its metabolomics, gene-expression profiling, tissue analysis software, and computational assets.